Sex Differences in the Pharmacokinetics of Cannabidiol and Metabolites Following Oral Administration of a Cannabidiol-Dominant Cannabis Oil in Healthy Adults

Abstract

Introduction:

Oral cannabidiol (CBD) product use is increasingly growing among women; however, there is a lack of data on sex differences in the pharmacokinetics (PKs) of CBD and its primary metabolites, 7-hydroxy-CBD (7-OH-CBD) and 7-carboxy-CBD (7-COOH-CBD), after repeated doses.

Materials and Methods:

The present study is a secondary analysis of data from a randomized, double-blind, placebo-controlled multiple-dose trial of a commercially available, CBD-dominant oral cannabis product. Healthy participants (n=17 males and 15 females) were randomized to receive 120 to 480 mg of CBD daily for 7 days. Dosing groups were pooled for all analyses due to sample size limitations. Analyses compared plasma PK parameters by sex, day, and sex×day.

Results:

For raw PK parameters for CBD and metabolites, there were no statistically significant effects of sex×day or sex (all p-values >0.05). For metabolite-to-parent ratios (MPRs) of AUC_0-t, there were significant effects of the sex×day interactions for 7-OH-CBD (F=6.89, p=0.016) and 7-COOH-CBD (F=5.96, p=0.021). For 7-OH-CBD, follow-up analyses showed significant simple effects of day within females (t=4.13, p<0.001), but not within males (t=0.34, p=0.73), such that 7-OH-CBD MPRs increased significantly from day 1 to 7 for females, but not for males. For 7-COOH-CBD, follow-up analyses revealed significant simple effects of day within females (t=8.24, p<0.001) and males (t=5.20, p<0.001), therefore 7-COOH-CBD MPRs increased significantly from day 1 to 7 in both sexes, but the increase was significantly greater among females than among males. Within dosing days, there were no statistically significant simple effects of sex on MPRs of 7-OH-CBD or 7-COOH-CBD.

Conclusions:

Females exhibited greater relative exposure to CBD metabolites in plasma over time, which may reflect sex differences in CBD metabolism or elimination. Further research assessing the safety implications of higher relative exposure to CBD metabolites over longer periods of time is warranted to mirror typical consumer use patterns.

Get full access to this article

View all access options for this article.

References

Millar

, Stone

, Bellman

, et al. A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol, 2019; 85:1888–1900; doi: 10.1111/bcp.14038

Huestis

. Human cannabinoid pharmacokinetics. Chem Biodivers, 2007; 4(8):1770–1804.

Mazur

, Lichti

, Prather

, et al. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos, 2009; 37(7):1496–1504.

Jiang

, Yamaori

, Takeda

, et al. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci, 2011; 89(5–6):165–170; doi: 10.1016/j.lfs.2011.05.018

Beers

, Fu

, Jackson

. Cytochrome P450–catalyzed metabolism of cannabidiol to the active metabolite 7-hydroxy-cannabidiol. Drug Metab Dispos, 2021; 49(10):882–891; doi: 10.1124/dmd.120.000350

Epidiolex Package Insert. (GB, Inc., ed.) FDA approved 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf [Last accessed: October 17, 2022].

Matheson

, Sproule

, Di Ciano

, et al. Sex differences in the acute effects of smoked cannabis: Evidence from a human laboratory study of young adults. Psychopharmacology (Berl), 2020; 237(2):305–316; doi: 10.1007/s00213-019-05369-y

Lunn

, Diaz

, O'Hearn

, et al. Human pharmacokinetic parameters of orally administered Δ9-tetrahydrocannabinol capsules are altered by fed versus fasted conditions and sex differences. Cannabis Cannabinoid Res, 2019; 4(4):255–264; doi: 10.1089/can.2019.0037

Nadulski

, Pragst

, Weinberg

, et al. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit, 2005; 27(6):799–810.

10.

Sholler

, Strickland

, Spindle

, et al. Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. Addict Biol, 2021; 26(4):e12968; doi: 10.1111/adb.12968

11.

Cooper

, Craft

. Sex-dependent effects of cannabis and cannabinoids: A translational perspective. Neuropsychopharmacology, 2018; 43(1):34–51; doi: 10.1038/npp.2017.140

12.

Goodman

, Wadsworth

, Schauer

, et al. Use and perceptions of cannabidiol products in Canada and in the United States. Cannabis Cannabinoid Res, 2022; 7(3):355–364; doi: 10.1089/can.2020.0093

13.

Knaub

, Sartorius

, Dharsono

, et al. A novel self-emulsifying drug delivery system (SEDDS) based on VESIsorb((R)) formulation technology improving the oral bioavailability of cannabidiol in healthy subjects. Molecules, 2019; 24(16); doi: 10.3390/molecules24162967

14.

Spindle

, Cone

, Goffi

, et al. Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users. Drug Alcohol Depend, 2020; 211:107937; doi: 10.1016/j.drugalcdep.2020.107937

15.

Arkell

, Kevin

, Vinckenbosch

, et al. Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials. Addict Biol, 2021; e13125; doi: 10.1111/adb.13125

16.

Child

, Tallon

. Cannabidiol (CBD) dosing: Plasma pharmacokinetics and effects on accumulation in skeletal muscle, liver and adipose tissue. Nutrients, 2022; 14(10):2101; doi: 10.3390/nu14102101

17.

Barras

, Legg

. Drug dosing in obese adults. Aust Prescr, 2017; 40(5):189–193; doi: 10.18773/austprescr.2017.053

18.

Peters

, Mosesova

, MacNair

, et al. Safety, pharmacokinetics and pharmacodynamics of spectrum yellow oil in healthy participants. J Anal Toxicol, 2022; 46(4):393–407; doi: 10.1093/jat/bkab026

19.

Klawitter

, Sempio

, Morlein

, et al. An atmospheric pressure chemical ionization MS/MS assay using online extraction for the analysis of 11 cannabinoids and metabolites in human plasma and urine. Ther Drug Monit, 2017; 39(5):556–564; doi: 10.1097/FTD.0000000000000427

20.

Kulpa

, Eglit

, Hill

, et al. Serum markers of bone turnover following controlled administration of two medical cannabis products in healthy adults. Cannabis Cannabinoid Res, 2022; doi: 10.1089/can.2022.0181

21.

Soldin

, Chung

, Mattison

. Sex differences in drug disposition. J Biomed Biotechnol, 2011; 2011:187103; doi: 10.1155/2011/187103

22.

Scandlyn

, Stuart

, Rosengren

. Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol, 2008; 4(4):413–424; doi: 10.1517/17425255.4.4.413

23.

Nicolas

J-M

, Espie

, Molimard

. Gender and interindividual variability in pharmacokinetics. Drug Metab Rev, 2009; 41(3):408–421; doi: 10.1080/10837450902891485

24.

Bigos

, Pollock

, Stankevich

, et al. Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: An updated review. Gend Med, 2009; 6(4); doi: 10.1016/j.genm.2009.12.004

25.

Degen

, Phillips

. Variability of gastrointestinal transit in healthy women and men. Gut, 1996; 39(2):299–305.

26.

Schuetz

, Furuya

, Schuetz

. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther, 1995; 275(2):1011–1018.

27.

Zamek-Gliszczynski

, Chu

, Polli

, et al. Understanding the transport properties of metabolites: Case studies and considerations for drug development. Drug Metab Dispos, 2014; 42(4):650–664; doi: 10.1124/dmd.113.055558

28.

Bansal

, Paine

, Unadkat

. Comprehensive predictions of cytochrome P450 (CYP)-mediated in vivo cannabinoid-drug interactions based on reversible and time-dependent CYP inhibition in human liver microsomes. Drug Metab Dispos, 2022; doi: 10.1124/dmd.121.000734

29.

Stieger

, Fattinger

, Madon

, et al. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology, 2000; 118(2):422–430; doi: 10.1016/s0016-5085(00)70224-1

30.

Andrade

, Chalasani

, Björnsson

, et al. Drug-induced liver injury. Nat Rev Dis Primers, 2019; 5(1):1–22; doi: 10.1038/s41572-019-0105-0

31.

Chan

, Benet

. Measures of BSEP inhibition in vitro are not useful predictors of DILI. Toxicol Sci, 2018; 162(2):499–508; doi: 10.1093/toxsci/kfx284

32.

Miszczuk

, Barosso

, Larocca

, et al. Mechanisms of canalicular transporter endocytosis in the cholestatic rat liver. Biochim Biophys Acta Mol Basis Dis, 2018; 1864(4 Pt A):1072–1085; doi: 10.1016/j.bbadis.2018.01.015

33.

, Yang

, Zhang

, et al. The pathological mechanisms of estrogen-induced cholestasis: Current perspectives. Front Pharmacol, 2021; 12:761255; doi: 10.3389/fphar.2021.761255

34.

Kashuba

, Nafziger

. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet, 1998; 34(3):203–218; doi: 10.2165/00003088-199834030-00003

35.

Damoiseaux

, Proost

, Jiawan

VCR

, et al. Sex differences in the pharmacokinetics of antidepressants: Influence of female sex hormones and oral contraceptives. Clin Pharmacokinet, 2014; 53(6):509–519; doi: 10.1007/s40262-014-0145-2

36.

Peters

, MacNair

, Mosesova

, et al. Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ9-tetrahydrocannabinol: A pilot study. Eur J Clin Pharmacol, 2022; 78(2):259–265; doi: 10.1007/s00228-021-03232-8

37.

Boggs

, Nguyen

, Morgenson

, et al. Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol. Neuropsychopharmacology, 2018; 43(1):142–154; doi: 10.1038/npp.2017.209

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB